|
|
|
|
Syros Pharmaceuticals Inc (NASDAQ: SYRS) |
|
|
|
| |
SYRS $0.0223
$-0.0017 
-7.08%
|
Volume (M):
163
Open :
0.02 52 Wk Avg :
1.51
|
SYRS $0.0223
$-0.0017
-7.08%
|
Volume (M):
163
Open :
0.02 52 Wk Avg :
1.51
|
|
Syros Pharmaceuticals Inc SYRS.NASDAQ Chart and Quote
|
SYRS Today's High:
|
$0.0286
|
SYRS Shares One Week Perf:
|
-10.8 %
|
| SYRS Today's Low: |
$ 0.02 |
SYRS Shares 30 Day Performance: |
-34.8 % |
| Number of SYRS Shares Traded (M): |
163 |
SYRS Share Price 52 Wk High: |
$ 6.93 |
| Value of SYRS's Shares Traded (M$): |
$ 4 |
SYRS Share Price 52 Wk Avg: |
$1.51 |
| Share Price at the Open: |
$0.02 |
SYRS's Share Price 52 Wk Low: |
$0.02 |
Syros Pharmaceuticals Inc stock dropped by -36.83 % during the trailing 30 days, this brings the share price to -13.57% during the Q2 of 2025. Syros Pharmaceuticals Inc stock is currently trading on the NASDAQ by -98.5% below its 52 week average.
Syros Pharmaceuticals Inc 's share price is delayed for 15 minutes
Select the Period on the chart to see the SYRS.NASDAQ's share price performance, or type custom period of your choice
SYRS Company Profile >> Share performance within Major Pharmaceutical Preparations Industry >> Compare SYRS to its Benchmarks |
News about Syros Pharmaceuticals Inc's Stock Splits and Dividends |
|
December 19, 2023
Syros Pharmaceuticals, a leading biopharmaceutical company dedicated to revolutionizing the treatment of hematologic malignancies, recently revealed the pricing details of its underwritten offering of common stock and pre-funded warrants. The offering, consisting of 4,939,591 shares of common stock and pre-funded warrants to purchase 5,242,588 shares, is expected to raise $45.0 million. This article will analyze the implications of the offering on Syros Pharmaceuticals and provide an overview of the current market performance of the company s shares.
1. The Pricing Details:
Syros Pharmaceuticals has priced its underwritten offering at $4.42 per share for common stock and $4.419 per share for pre-funded warrants. The offering is an opportunity for the company to raise additional funds and support its continued efforts to develop novel therapies for hematologic malignancies.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
